---
title: "Key facts: Merck & Co., Inc. Q2 Sales $16.6B; sac-TMT Advances"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294924968.md"
description: "MRK Q2 sales $16.6B (+5% YoY), Keytruda $8.4B, Winrevair $588M (+75%). GAAP net loss $1.34B; adjusted loss $0.13/sh due to $5.7B acquisition charge. 2026 sales guide $66.3–67.3B; adj EPS $2.66–2.76. 3 sourcesMerck (MRK) advances sac-TMT, an ADC targeting Trop-2 in multiple Phase 3 cancer trials; company calls it a cornerstone that could reshape KEYNOTE-189–style lung cancer combination strategies StocktwitsDisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources."
datetime: "2026-08-05T07:14:57.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294924968.md)
  - [en](https://longbridge.com/en/news/294924968.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294924968.md)
generator: "portal-rs"
---

# Key facts: Merck & Co., Inc. Q2 Sales $16.6B; sac-TMT Advances

-   MRK Q2 sales $16.6B (+5% YoY), Keytruda $8.4B, Winrevair $588M (+75%). GAAP net loss $1.34B; adjusted loss $0.13/sh due to $5.7B acquisition charge. 2026 sales guide $66.3–67.3B; adj EPS $2.66–2.76. 3 sources
-   Merck (MRK) advances sac-TMT, an ADC targeting Trop-2 in multiple Phase 3 cancer trials; company calls it a cornerstone that could reshape KEYNOTE-189–style lung cancer combination strategies Stocktwits

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.

### Related Stocks

- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [Merck Targets $70B Pipeline as It Prepares for KEYTRUDA Exclusivity Loss](https://longbridge.com/en/news/298558395.md)
- [NewEdge Advisors LLC Purchases 41,950 Shares of Merck & Co., Inc. $MRK](https://longbridge.com/en/news/298434406.md)
- [IPH: Key late-stage data and partnerships position the pipeline for major milestones and growth](https://longbridge.com/en/news/298965815.md)
- [AI Risks to Enter 60–80% of Liability and Cyber Insurance Underwriting by 2028, ScienceSoft Predicts](https://longbridge.com/en/news/298612310.md)
- [IMNM: Filed NDA for varegacestat and innovative ADC pipeline signal strong oncology momentum](https://longbridge.com/en/news/298941431.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**